{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-002591","form_type":"8-K","ticker":"HBIO","cik":"0001123494","company_name":"HARVARD BIOSCIENCE INC","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.361825+00:00","generated_at":"2026-06-02T16:06:06.700687+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Harvard Bioscience Q1 revenue falls 18% to $24.5M; posts GAAP net loss of $4.7M","bullets":["Revenue $24.5M, down 18% YoY from $30.0M; gross margin 60.3% vs 61.2%.","GAAP net loss $4.7M ($0.11 loss per share) vs net income $0.6M ($0.01 EPS) a year ago.","Adjusted operating income $1.2M, down from $4.4M; adjusted EBITDA $1.6M, down from $4.8M.","CEO cites APAC market headwinds and strong prior-year comp; cost reduction initiative announced post-quarter.","Expects solid growth in second half aided by new product launches and Chinese stimulus."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-002591","json":"https://secwatch.observer/filing/0001171843-24-002591.json","markdown":"https://secwatch.observer/filing/0001171843-24-002591.md","text":"https://secwatch.observer/filing/0001171843-24-002591.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1123494/000117184324002591/0001171843-24-002591-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1123494/000117184324002591/f8k_050724.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T16:06:06.700687+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b354b6bc8034ce50ea5485330c10d710fa9f0e5c","claim":"HARVARD BIOSCIENCE INC reported first quarter ended March 31, 2024 results: revenue $24.5, net income $(4.7), EPS $(0.11) per diluted share.","evidence_excerpt":"continue to expect solid growth in the second half.” Financial Results Summary Three Months Ended March 31, (unaudited, $ in millions except per share data) 2024 2023 Revenues $ 24.5 $ 30.0 Gross margin 60.3 % 61.2 % Operating (loss) income (GAAP) $ (2.3 ) $ 1.7 Adjusted operating income $ 1.2 $ 4.4 Net (loss) income (GAAP) $ (4.7 ) $ 0.6 Diluted (loss)","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1123494/000117184324002591/0001171843-24-002591-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$24.5"},{"label":"Net income","value":"$(4.7)"},{"label":"EPS","value":"$(0.11) per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}